XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenetic Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.93−0.06 (-3.02%)
Close on Oct 19, 2026
- Market cap
- $4.43M
- P/E (TTM)
- –
- Dividend yield
- –
Xenetic Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Market Cap | $4.52M | $164.85M |
| Enterprise Value | -$1.95M | $87.06M |
| PS Ratio | 1.39 | 3.60 |
| PB Ratio | 0.74 | 2.03 |
| P/TBV Ratio | 0.74 | 2.31 |
Enterprise value
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| EV / Sales | -0.60 | 2.43 |
Income (trailing twelve months)
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Revenue | $3.26M | $57.94M |
| Operating Income | -$2.64M | -$21.44M |
| Net Income | -$2.48M | -$22.46M |
| EBITDA | -$2.64M | -$16.91M |
| EPS (Diluted) | -$1.21 | -$0.83 |
Margins
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Operating Margin | -81.0% | -44.5% |
| Profit Margin | -75.9% | -39.2% |
| EBITDA Margin | -81.0% | -31.3% |
Returns
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -47.0% | -53.1% |
| Return on Assets (ROA) | -40.2% | -41.0% |
| Return on Capital Employed (ROCE) | -43.5% | -37.8% |
Growth
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 33.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 20.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 46.8% | 6.42% |
Balance sheet
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $6.47M | $62.42M |
| Net Cash (Debt) | $6.47M | $15.68M |
| Net Cash Per Share | $2.76 | $0.66 |
| Equity (Book Value) | $6.07M | $48.79M |
| Book Value Per Share | $2.59 | $1.36 |
| Tangible Book Value | $6.07M | $23.06M |
| Working Capital | $5.76M | $75.77M |
Financial position
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Current Ratio | 7.43 | 3.30 |
| Quick Ratio | 7.23 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$2.31M | -$12.35M |
Efficiency
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.53 | 0.38 |
| Revenue Per Employee | $1.63M | $398.96K |
| Profits Per Employee | -$1.24M | -$703.34K |
| Employee Count | 2 | 74 |
Dividends and yields
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -54.7% | -22.7% |
Shares
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 2,343,180 | 58,179,650 |
| Shares Change (YoY) | 34.7% | 11.1% |
| Shares Change (QoQ) | 2.15% | 0.54% |
| Float | 2,056,400 | 49,173,100 |
| Shares Held by Insiders | 12.2% | 11.6% |
| Shares Held by Institutions | 6.49% | 59.4% |
Taxes
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Xenetic Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | -37.20 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Xenetic Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.